Abstract: Systems and methods for recreating images from undersampled magnetic resonance imaging (MRI) image data remove artifacts from the undersampling. Using trained transformer networks, undersampled k-space data can be acquired and the networks can predict additional projected radial MRI k-space data from the undersampled radial MRI k-space data. Images with fewer artifacts can then be generated.

Abstract: The invention relates to a multi-fuel engine comprising a primary fuel supply and at least a secondary fuel supply. The primary and at least secondary fuels are arranged to mix with each other and with air for combustion in one or more cylinders of the engine in use. One or more electronic control units (ECU) are provided to control one or more supply characteristics of the primary and/or at least secondary fuel(s) in use. The engine includes a mass air flow (MAF) sensing means. At least one of the ECUs is arranged to receive one or more signals from the MAF sensing means to control, at least partially, one or more supply characteristics of the primary fuel. In addition, the ECU and/or a further ECU is arranged to receive one or more signals from the MAF sensing means to control, at least partially, one or more supply characteristics of the at least secondary fuel.

Abstract: 3D cine MR angiography systems and methods are disclosed for use during the steady state intravascular distribution phase of ferumoxytol. The 3D cine MRA technique enables improved delineation of cardiac anatomy in pediatric patients undergoing cardiovascular MRI.

Abstract: A feed assembly for that operates at different frequency bands (e.g., low, mid and high frequency bands) is provided herein. The feed assembly includes a feed horn common to low, mid and high frequency bands, a coaxial polarizer to launch signals in the low band frequency band, a coaxial orthomode transducer (OMT) to launch signals in the low band frequency band and supports the mid and high frequency bands, and a polyrod disposed in a center conductor of the feed assembly, the polyrod common to the mid and high frequency bands. The feed assembly includes a tri-band feed assembly having different portions to support signals in the low frequency band and signals in the mid and high frequency bands.

Abstract: A feed assembly for that operates at different frequency bands (e.g., low, mid and high frequency bands) is provided herein. The feed assembly includes a feed horn common to low, mid and high frequency bands, a coaxial polarizer to launch signals in the low band frequency band, a coaxial orthomode transducer (OMT) to launch signals in the low band frequency band and supports the mid and high frequency bands, and a polyrod disposed in a center conductor of the feed assembly, the polyrod common to the mid and high frequency bands. The feed assembly includes a tri-band feed assembly having different portions to support signals in the low frequency band and signals in the mid and high frequency bands.

Abstract: The invention relates to a multi-fuel engine comprising a primary fuel supply and at least a secondary fuel supply. The primary and at least secondary fuels are arranged to mix with each other and with air for combustion in one or more cylinders of the engine in use. One or more electronic control units (ECU) are provided to control one or more supply characteristics of the primary and/or at least secondary fuel(s) in use. The engine includes a mass air flow (MAF) sensing means. At least one of the ECUs is arranged to receive one or more signals from the MAF sensing means to control, at least partially, one or more supply characteristics of the primary fuel. In addition, the ECU and/or a further ECU is arranged to receive one or more signals from the MAF sensing means to control, at least partially, one or more supply characteristics of the at least secondary fuel.

Abstract: 3D cine MR angiography systems and methods are disclosed for use during the steady state intravascular distribution phase of ferumoxytol. The 3D cine MRA technique enables improved delineation of cardiac anatomy in pediatric patients undergoing cardiovascular MRI.

Abstract: This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-? Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-?, such as rheumatoid arthritis; inflammation; psoriasis; septic shock; graft rejection; cachexia; anorexia; congestive heart failure; post ischaemic reperfusion injury; inflammatory disease of the central nervous system; inflammatory bowel disease; insulin resistance; HIV infection; cancer; chronic obstructive pulmonary disease (COPD); and asthma. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in the inhibition of TACE, and in the treatment of conditions that are ameliorated by the inhibition of TACE.

Abstract: This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1$g(a) and p300) and thereby inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer.

Abstract: In a method and apparatus for classifying plaque in a blood vessel of a living subject using magnetic resonance imaging, a first magnetic resonance image is produced with a first intensity distribution of a cross-section of a vessel containing plaque, and a contrast agent is injected into the vascular system and a second magnetic resonance image of the cross-section of the vessel is produced with a second intensity distribution after a first time duration following the contrast agent injection, and a third magnetic resonance image of the cross-section of the vessel is produced with a third intensity distribution after a second time duration following the injection of the contrast agent, and the plaque is classified dependent on the respective intensity distributions of the magnetic resonance images.

Abstract: A cleaning appliance vacuum cleaner includes a main body having a rear portion and a roller structure such as side wheels arranged to allow the main body to travel across a floor surface. In normal use, the rear portion is spaced from the floor surface. The rear portion carries a wheel arranged so that, if the main body is tilted so that the rear portion is brought towards the floor, the wheel contacts the floor surface. Thus, the cleaner may be used in a tipped-back position without causing damage to the floor surface as the cleaner is dragged along by the user by a hose attached to the main body. The size and position of the wheel is determined so that, when the cleaner is tipped back, the center of gravity of the main body acts to return the main body to an upright position.

Abstract: This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C9-10heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated C17alkylene group having a backbone length of 4 or less; with the proviso that if A is unsubstituted benzothiazol-2-yl, then Q is an unsaturated group; and with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the a-position; and with the proviso that A is not benzimidazol-2-yl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

Abstract: This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: —O—C(?O)— or —C(?O)—O— or —C(?O)—; Cy is a cyclyl group and is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q2 is an acid leader group, and is independently: C1-8alkylene; and is optionally substituted; or: Q2 is an acid leader group, and is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or C1-7alkylene-C5-20aryl

Abstract: This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: wherein: Cy is independently a cyclyl group; Q1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J1 is independently a covalent bond or —C(?;O)—; J2 is independently —C(?O)— or —S(?O)2—; Q2 is independently an acid leader group; wherein: Cy is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is independently: a covalent bond; C1-7alkylene; or C1-7alkylene-X—C1-7alkylene, —X—C1-7alkylene, or C1-7alkylene-X—, wherein X is —O— or —S—; and is optionally substituted; Q2 is independently: C4-8alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q2 is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or, C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and has a backbone le

Abstract: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(?O)2NR1— and —NR1S(?O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(?O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

Abstract: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(?O)2NR1— and —NR1S(?O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(?O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

Abstract: In a method and apparatus for classifying plaque in a blood vessel of a living subject using magnetic resonance imaging, a first magnetic resonance image is produced with a first intensity distribution of a cross-section of a vessel containing plaque, and a contrast agent is injected into the vascular system and a second magnetic resonance image of the cross-section of the vessel is produced with a second intensity distribution after a first time duration following the contrast agent injection, and a third magnetic resonance image of the cross-section of the vessel is produced with a third intensity distribution after a second time duration following the injection of the contrast agent, and the plaque is classified dependent on the respective intensity distributions of the magnetic resonance images.

Abstract: A segmented cine MR pulse sequence of the “TrueFISP”-type having a short repetition time TR is used to acquire MR data during a single breath hold. In the resulting cine images, the blood and the myocardium have distinctly different image contrasts.

Abstract: A three-dimensional gadolinium-enhanced MR study of e.g. the patient's thoracic vasculature is carried out while the patient holds his or her breath. Acquisition of all data in each three-dimensional partition takes place during one and only one heartbeat. By synchronizing the MR pulse sequence to the patient's cardiac cycle, and advantageously by acquiring the MR data during the diastolic phase of the cardiac cycle, image artifacts caused by cardiac motion and pulsatile flow are eliminated or minimized.

Abstract: An MR pulse sequence for conducting fat- or water-suppressed multislice MR studies. Saturation prepulses are used less frequently than is conventional practice. Each time at least one saturation prepulse is used to saturate all slices in a group of slices, one line of MR data is acquired from each slice in the group without using any other saturation prepulse.